Pharmacokinetic Differences Between Lansoprazole Enantiomers in Rats
- 1 November 1998
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 50 (11), 1241-1245
- https://doi.org/10.1111/j.2042-7158.1998.tb03340.x
Abstract
Because limited information is available about potential differences between the pharmacokinetics and pharmacodynamics of the enantiomers of lansoprazole, the enantioselective pharmacokinetics of the compound have been investigated in rats. There was a noticeable difference between the serum levels of the enantiomers of lansoprazole and of their metabolites, 5-hydroxylansoprazole enantiomers, after oral administration of the racemate (50 mg kg−1) to rats. Cmax (maximum serum concentration) and AUC (area under the serum concentration-time curve) for (+)-lansoprazole were 5–6 times greater than those for (—)-lansoprazole, whereas for (+)-5-hydroxylansoprazole both values were significantly smaller than those for the (—) enantiomer. CLtot/F values (where CLtot is total clearance and F is the fraction of the dose absorbed) for (+)-lansoprazole were significantly smaller than those for the (—) enantiomer. There was no significant difference between the absorption rate constants of the lansoprazole enantiomers in the in-situ absorption study. The in-vitro protein-binding study showed that binding of (+)-lansoprazole to rat serum proteins was significantly greater than for the (—) enantiomer. The in-vitro metabolic study showed that the mean metabolic ratio (45.9%) for (—)-lansoprazole was significantly greater than that (19.8%) for the (+) enantiomer in rat liver microsomes at 5.6 μM lansoprazole. These results show that the enantioselective disposition of lansoprazole could be a consequence of the enantioselectivity of plasma-protein binding and the hepatic metabolism of the enantiomers.Keywords
This publication has 12 references indexed in Scilit:
- Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects*Clinical Pharmacology & Therapeutics, 1997
- Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjectsEuropean Journal of Clinical Pharmacology, 1997
- Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status*Clinical Pharmacology & Therapeutics, 1997
- Effects of Erythromycin, Clarithromycin and Rokitamycin on Nifedipine Metabolism in Rats.Biological & Pharmaceutical Bulletin, 1997
- Effect of Activated Charcoal and Atropine on Absorption and/or Exsorption of Organophosphorus Compounds in RatsJournal of Pharmacy and Pharmacology, 1996
- Determination of R(+)- and S(–)-Lansoprazole Using Chiral Stationary-Phase Liquid Chromatography and Their Enantioselective Pharmacokinetics in HumansPharmaceutical Research, 1996
- Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cellsBiochemical Pharmacology, 1991
- The Site of Inversion of R(–)-Ibuprofen: Studies Using Rat In-situ Isolated Perfused Intestine/liver PreparationsJournal of Pharmacy and Pharmacology, 1991
- Slow Omeprazole Metabolizers Are Also Poor S-Mephenytoin HydroxylatorsTherapeutic Drug Monitoring, 1990
- The intestinal dialysis of intravenously administered phenytoin by oral activated charcoal in rats.Journal of Pharmacobio-Dynamics, 1987